Loader

Please wait...

Canadian Pharmacists Association
Canadian Pharmacists Association
Share
Facebook Share
Twitter Share
LinkedIn Share
Google Plus Share
Email Share

CPHS 2020 Banner

Current CPHS 2020 Projects

Resources

What is CPHS 2020?

There is emerging evidence supporting the health benefits to patients of pharmacist-delivered health care services, however, their scope of practice (unlike other healthcare professionals) is not harmonized across Canada.

That’s why the Canadian Pharmacists’ Harmonized Scope (CPHS) 2020 was launched in 2017 as an initiative which aspires to define, describe and develop a national, forward-looking harmonized scope of practice as well as describe patient benefits delivered by pharmacists working to full scope.

Initial work involved extensive stakeholder consultations resulting in the development of four key domains that would improve patient care and contribute to health care efficiencies — prescriptive authority, dispensing authority, medication administration authority and health test authority.

As work continued it became clear that there were challenges with such a broad review and evaluation of evidence across the four domains of pharmacist-delivered services.

For this reason, CPHS 2020 refocused its efforts — moving from a broad-based scope initiative to a more focused approach in specific therapeutic areas.

Covid FAQ

CPHS 2020: Four key domains developed to improve patient care and improve health care efficiencies

CPHS 2020 Steering Committee

CPHS 2020 has a Steering Committee whose purpose is to provide information, advice and recommendations to map the way forward to achieve a harmonized scope of practice for pharmacists within identified therapeutic areas across Canada.

The mandate of the Steering Committee is to provide guidance on the integration of the CPHS 2020 framework which identifies the value of pharmacist-delivered services across the four domains into the broader health system.  

Other responsibilities:

  • Review evidence provided by the Evidence Groups about health and system benefits to build a strategy for the development of advocacy initiatives;
  • Provide input and advice on knowledge translation initiatives, as they relate to the identified therapeutic areas to ensure they meet the needs of the pharmacy community; and
  • Be ambassadors within respective jurisdictions of the CPHS 2020 framework among all relevant stakeholder groups.

The Committee reports to and takes direction from the CPhA Board of Directors. 

Current CPHS 2020 Projects

Pharmacists Opioid Stewardship Initiative (POSI)

What it is

This project focuses on the scope enhancement and harmonization that enables pharmacists to be opioid stewards.

The Pharmacists’ Opioid Stewardship Initiative (POSI) is a multi-year initiative.  It involves synthesizing evidence demonstrating the value of pharmacists’ services in opioid stewardship to both patients and the health system across the four domains of scope of practice authority. The POSI vision: Pharmacists are fully enabled to meet patient and health system needs as opioid stewards universally across Canada.

Armed with this evidence, the profession will be in a better position to advocate governments for harmonized scope of practice for pharmacist services in opioid therapy management for their patients.

The goal is to use POSI as a model for future phases of CPHS 2020 work – taking a patient and health system needs approach to identify subsequent areas of focus.

Why it matters

The opioid epidemic is one of the most challenging and complex health crises in Canada today. According to the federal government, more than 15,000 Canadians have been killed by opioids over the last four years and close to 20,000 people have been hospitalized for opioid-related poisoning. For this reason, POSI is a relevant and timely project which could further help vulnerable Canadians manage their opioid therapy.

Why pharmacists and opioid stewardship

Pharmacists are in an ideal position to be opioid stewards as they are the most accessible health care provider and could fill a critical system gap. 

They are often the first health care provider to observe signs of opioid use disorder. Many are already helping patients by optimizing patients’ opioid therapy through pain assessment, medication reviews, monitoring for interactions, medication administration, exemptions for prescribing suboxone and methadone, ensuring appropriate dosing, and consulting on switching or tapering of opioids.

As well there is a considerable existing and emerging evidence base, with existing criteria and a validated framework to guide an evidence review.  

CPhA has been a strong advocate for more opportunities and supports for pharmacists in the management of opioid therapy, including expansion of scope of practice for prescribing and adapting opioids and other substances.

COVID-19 exemptions

COVID-19 pandemic temporary exemptions have been made under the Controlled Drugs and Substances Act (CDSA), creating an opportunity to provide continuity of care to some of our most vulnerable Canadians to ensure that their care is not interrupted, especially in times where they may be experiencing more stress, anxiety and isolation.

These exemptions permit pharmacists to care for their patients by extending prescriptions, transferring prescriptions to other pharmacists, receiving verbal orders and allowing other pharmacy employees to deliver prescriptions of controlled substances to patients’ homes or other locations where they may be. In some provinces, pharmacists are also now permitted to adapt (i.e. modify the dosage, formulation or regimen) prescription-controlled drugs and substances to help in the care of their patients.   One of the immediate goals of the POSI initiative is to ensure these temporary exemptions for pharmacists prescribing are made permanent.

How is POSI structured

POSI is comprised of two groups:  The Opioid Practice Group and the Opioid Evidence Group 

The Opioid Practice Group

The mandate of the Opioid Practice Group is to provide advice to CPhA on the POSI including contributing to the vision, validating and advising on the goals to achieve the vision, as well as providing expertise on tactics to reach those goals.

The Opioid Evidence Group

The mandate of the Opioid Evidence Group is to synthesize the existing evidence in the area of pharmacist opioid stewardship specifically, the value of pharmacist-delivered services in the area as it pertains to the four domains identified in the CPHS 2020.

Resources

Health Canada: Controlled Drugs and Substances Act (CDSA)

Related

Need more information?

Contact:

Shelita Dattani
Director, Practice Development and Knowledge Translation
Email: sdattani@pharmacists.ca